This research aimed to examine the effectiveness of artificial intelligence applications in asthma and chronic obstructive pulmonary disease (COPD) outpatient treatment support in terms of patient health and public costs. The data obtained in the research using semiotic analysis, content analysis and trend analysis methods were analyzed with strengths, weakness, opportunities, threats (SWOT) analysis. In this context, 18 studies related to asthma, COPD and artificial intelligence were evaluated. The strengths of artificial intelligence applications in asthma and COPD outpatient treatment stand out as early diagnosis, access to more patients and reduced costs. The points that stand out among the weaknesses are the acceptance and use of technology and vulnerabilities related to artificial intelligence. Opportunities arise in developing differential diagnoses of asthma and COPD and in examining prognoses for the diseases more effectively. Malicious use, commercial data leaks and data security issues stand out among the threats. Although artificial intelligence applications provide great convenience in the outpatient treatment process for asthma and COPD diseases, precautions must be taken on a global scale and with the participation of international organizations against weaknesses and threats. In addition, there is an urgent need for accreditation for the practices to be carried out in this regard.

Background: This study aimed to investigate the diagnostic value of urea, creatinine and other blood parameters in patients with pneumonia diagnosed with chronic obstructive pulmonary disease (COPD) for the first time. Methods: In this retrospective study, patients who had been diagnosed with COPD for the first time and were diagnosed with pneumonia were included. A total of 193 patients were divided into three groups as COPD + pneumonia (n=123), COPD (n=36) and pneumonia (n=34). Results: In total, 59 women (48.0%) and 64 men (52.0%) from the COPD + pneumonia group, 13 women (36.1%) and 23 men (63.9%) from the COPD group, 21 women (61.8%) and 13 men (38.2%) from the pneumonia group were assessed. The mean age of the COPD + pneumonia group was 69.58±13.62, 66.28±12.55 for the COPD group and 53.97±19.72 for the pneumonia group. The highest values of C-reactive protein (CRP), urea, creatinine, white blood cells (WBC), neutrophils, eosinophils and hemoglobin were the highest in COPD + pneumonia group. CRP levels were significantly different between COPD + pneumonia group (p<0.05). The parameters urea, WBC and neutrophils were significantly different between COPD + pneumonia group and pneumonia group (p<0.05). There was a statistically significant difference between COPD and pneumonia groups in terms of neutrophils and eosinophils values (p0.05). On the other hand, the diagnostic value of CRP, WBC and neutrophils values were statistically significant (p<0.05). Conclusions: Elevation in WBC and neutrophil values in patients diagnosed with pneumonia have an important role in diagnosis of COPD.

This study aimed to investigate the effects of air pollution and urbanization on the rate of allergic rhinitis and COPD in Turkey. Allergy and COPD rates compiled from the Turkish Ministry of Health Statistical Yearbooks and air pollution and urbanization data from the World Bank Country Reports database were used in the study. According to the Ministry of Health data, rate data for allergy and COPD were currently provided from 2008 to 2022. Therefore, the study covered the years 2008–2022 as a time limit. The rate of allergy was 9.30% in 2008, it was 9.60% in 2022 and the average was 9.46 ± 3.03. The COPD rate showed a peak at 21.61% in 2020 but then fluctuated, making the average of 23.47% potentially misleading. Allergy rate remained relatively stable (9.30% to 9.60%). While the rate of COPD was 2.20% in 2008, it was 21.61% in 2020 and the average was 6.00 ± 2.54. The average air pollution value was 23.47 ± 0.88 micrograms per cubic meter and the average urbanization value was 73.50 ± 2.36. Health expenditures increased from 11.09% to 11.53% and the average was 10.38 ± 0.79. There was a statistically significant and positive relationship between allergy and urbanization (r = 0.564; p < 0.05). Similarly, there was a statistically significant and positive relationship between COPD and urbanization (r = 0.776; p < 0.01). There was no direct relationship between air pollution and both allergy and COPD (p > 0.05). According to the linear regression analysis results, the effect of urbanization on allergy was statistically significant and positive (B = 0.924; p < 0.05). The effect of urbanization on COPD rate was statistically significant and positive (B = 1.052; p < 0.01). Although air pollution is reported to be important for allergy and COPD, urbanization has emerged as an indirect factor effecting COPD rate. Since combating air pollution is more effective today than in the past, more studies and field research are needed on other disease causative factors brought about by urbanization.

Idiopathic pulmonary fibrosis (IPF) affects the tissue surrounding the alveoli and occurs when the lung tissue becomes thick and stiff for unknown reasons. Clinical findings are fairly well settled, but the molecular mechanisms of IPF are still poorly known. To further our understanding, we collected publicly available transcriptome dataset from IPF cohorts, grouped them according to sampling method [bronchoalveolar lavage (BAL), biopsy, blood], and performed comparative meta-transcriptome study to (I) unravel key pathways (II), set out differences in discovered genes, pathways, and functional annotation with respect to the sampling method, and (III) find biomarkers for early diagnosis. The resulting lists are also compared with DisGeNet reported genes, earlier work, and Kyoto encyclopedia of genes and genomes (KEGG) pathways. Several pathways are shared among BAL and biopsy samples while blood samples point to alternative pathways, indicating the noise in information obtained from these samples. Common to all sampling methods, interleukin-10 pathway and extracellular signaling pathways are pointed as further targets.

Background/aim: Despite advances in treatment, achieving effective and durable responses with chemotherapy remains a significant challenge in lung cancer management. This study investigates the effects of montelukast sodium (MLS) and desloratadine (DES), alone and in combination with cisplatin (CIS), on cell viability, apoptosis, cell cycle distribution, and antioxidant gene expression in A549 and DMS114 lung cancer cell lines. Materials and methods: Cells were treated with CIS, MLS, DES, and their combinations for 24–72 h. Cell viability was assessed via MTS assay; apoptosis and cell cycle progression were analyzed by flow cytometry. The expression of antioxidant-related genes (GPX4, GSR, GCLC) was quantified using qRT-PCR. Results: MLS and DES reduced cell viability individually in both cell lines in a dose- and time-dependent manner. The combination of CIS and MLS showed near-synergistic effects in A549 cells. The combination significantly enhanced apoptosis, particularly in DMS114 cells. In contrast, CIS combined with DES showed antagonistic interactions in both lines, with no significant increase in apoptosis compared to CIS alone. MLS combined with CIS also enhanced G0/G1 phase arrest, while the combination of DES and CIS had no additive effect on the cell cycle. DES alone or with CIS significantly upregulated GPX4 and GCLC, suggesting activation of antioxidant defense mechanisms. Meanwhile, MLS alone or combined with CIS led to a decrease in GCLC expression, indicating a possible impairment of redox homeostasis. Conclusion: MLS enhances CIS-induced cytotoxicity and apoptosis in lung cancer cells and modulates redox gene expression, potentially improving therapeutic efficacy. In contrast, DES may attenuate CIS activity through antioxidant gene upregulation. These findings support the potential of MLS as an effective adjuvant in CIS-based lung cancer treatment. However, the antagonistic effect observed with DES highlights the importance of careful evaluation of candidates for drug repurposing.